All Trials

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors—emphasizing platinum‑refractory/resistant ovarian cancer—who have exhausted standard therapy receive CUSP06 (AMT‑707), a cadherin‑6–targeted IgG1 antibody‑drug conjugate delivering an exatecan (topoisomerase‑I) payload, given IV every 21 days. Open‑label dose escalation with tumor‑specific expansions; key exclusions include prior topoisomerase‑I ADCs and active CNS disease.

ClinicalTrials.gov ID: NCT06234423

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (relapse ≤6 months after last platinum; ≤2 prior cytotoxic lines) receive carboplatin/paclitaxel plus oral defactinib, a reversible ATP-competitive FAK/Pyk2 inhibitor aimed at re-sensitizing to platinum. Primary aims are safety/tolerability and objective response by RECIST 1.1.

ClinicalTrials.gov ID: NCT03287271

A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Escalation and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable stage III/IV melanoma that has progressed after at least one prior systemic regimen and shows MC1R positivity on 68Ga‑VMT02 PET or 203Pb‑VMT01 SPECT receive [212Pb]VMT01, an MC1R-targeted peptide alpha-emitting radiopharmaceutical, as monotherapy or combined with nivolumab. Up to three [212Pb]VMT01 cycles are given about 8 weeks apart, with nivolumab dosed Q4W in combo cohorts; patients need ECOG 0–1 and adequate organ function, and key exclusions apply for prior radiopharmaceuticals and immune-related contraindications.

ClinicalTrials.gov ID: NCT05655312

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with high-risk NMIBC (CIS ± Ta/T1; includes BCG-unresponsive/exposed and those unfit for or declining cystectomy) receive intravesical PF-08052667 as monotherapy or combined with BCG and/or subcutaneous sasanlimab (anti–PD-1), with dose escalation/expansion to assess safety, PK, and preliminary antitumor activity. The molecular target of PF-08052667 has not been disclosed.

ClinicalTrials.gov ID: NCT07206225

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic HER2-expressing solid tumors (HER2-positive or HER2-low), including breast and gastric/GEJ cancers after standard therapies, receive IKS014, a HER2-targeting antibody–drug conjugate using a trastuzumab backbone linked to the microtubule inhibitor MMAF. Open-label dose escalation/expansion treats in 21-day cycles until progression to establish RP2D and assess antitumor activity.

ClinicalTrials.gov ID: NCT05872295

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with metastatic HR-positive, HER2-negative/low breast cancer receive STEMVAC, an intradermal multi-antigen plasmid DNA vaccine (targets CD105, YB-1, SOX2, CDH3, MDM2; GM-CSF–adjuvanted to elicit T-cell responses against cancer stem cell–associated proteins), added to either ongoing endocrine therapy plus a CDK4/6 inhibitor (first/second line) or to capecitabine after progression on endocrine therapy. Suitable for ECOG 0–1 patients with measurable disease; includes serial biopsies and immunologic monitoring.

ClinicalTrials.gov ID: NCT07112053

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer that is BRCA-mutated and/or HRD-positive, with prior PARP inhibitor exposure and ≤3 prior lines, receive olaparib plus cirtuvivint. Cirtuvivint is an oral CLK/DYRK inhibitor that modulates pre-mRNA splicing and downregulates Wnt-pathway gene expression; two intermittent dosing schedules are tested with continuous olaparib 300 mg BID.

ClinicalTrials.gov ID: NCT06856499

A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal cancer (after 1–2 prior lines) or pancreatic ductal adenocarcinoma (after exactly 1 prior line), ECOG 0–1, receive monotherapy GSK5764227 (HS-20093), a B7-H3–targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, at cohort-specific dose levels. Excludes active CNS mets, significant cardiovascular/hepatic/renal disease, prior topo‑I ADCs, and viral hepatitis; tumor tissue required for CRC and requested for PDAC.

ClinicalTrials.gov ID: NCT06885034

A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA‑A*02:01–positive unresectable or metastatic cutaneous melanoma (post–PD‑1) or synovial sarcoma needing further therapy receive autologous PRAME‑targeted TCR‑T cells (ACTengine IMA203) after lymphodepletion plus low‑dose IL‑2, combined with a PRAME mRNA vaccine (mRNA‑4203) to boost PRAME‑specific T‑cell responses. Key exclusions include active brain metastases, significant autoimmune/cardiac disease, prior allogeneic transplant, active viral infections, and hypersensitivity to study agents.

ClinicalTrials.gov ID: NCT06946225

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced/metastatic solid tumors (excluding HCC, sarcomas, gliomas) who have progressed on or are unsuitable for standard therapy receive PRTH-101, an anti‑DDR1 monoclonal antibody intended to disrupt collagen-mediated T‑cell exclusion, either as monotherapy or combined with pembrolizumab. Suitable for ECOG 0–1 with treated/stable CNS disease only; key exclusions include active autoimmune disease on immunosuppression, uncontrolled infections, and recent systemic therapy or radiation.

ClinicalTrials.gov ID: NCT05753722